Infectious Disease

As health officials respond to ongoing concerns, Nathan Ott, PharmD, joined to discuss key hantavirus facts that pharmacists can relay to their communities.

By late February 2026, national data from the CDC reveal a test positivity rate of 9.1%, the highest recorded for the entire season at that point.

Despite WHO officials stating that risks from the outbreak remain low, experts are acting urgently to uncover details and provide support.

Local pharmacies deliver rapid flu, COVID-19, strep, and urinary tract infection tests with same-day treatment, easing access gaps and cutting urgent care costs.

Phase 3 data show a 6-valent Lyme vaccine cuts confirmed cases by 73%, paving the way for 2026 filings and new prevention options.

This landmark decision follows previous approvals for adults 60 years and older, as well as those aged 50 to 59 years at increased risk.

Pharmacists are taking the lead to combat misinformation on measles and preserve the nation’s fragile elimination status.

Phase 3 trials show once-daily bictegravir/lenacapavir keeps HIV suppressed after switching regimens, with strong safety and better satisfaction for complex-treatment patients.

HIV care faces challenges from persistent stigmas and misinformation, hindering effective prevention and treatment integration into primary health care.

With infectious disease rates expected to jump as US vaccine schedules are reworked, antimicrobial stewardship programs are seeking community pharmacists.

GSK announces promising phase 3 trial results for bepirovirsen, a potential treatment for chronic hepatitis B, showing significant functional cure rates.

The administration announces back-to-back approvals for oral therapies used to treat uncomplicated urogenital gonorrhea.

Antibiotics are a prominent medication class reserved for helping patients fight bacterial infections.

The role of community pharmacists is expanding to combat antibiotic resistance and enhance antimicrobial stewardship.

Multifaceted antimicrobial stewardship initiatives significantly enhance antibiotic prescribing practices for respiratory infections, improving patient outcomes.

In an exploration of the National Retail Data Monitor, researchers determine how OTC sales contributed to disease surveillance.

From verifying vaccination status to administering immunizations, pharmacists can mitigate the spread of various infectious diseases.

Amid recent measles outbreaks in Texas and Ohio, researchers aim to understand MMR vaccine coverage following postelimination outbreaks throughout the country.

Among older adults with Medicare, researchers investigated national influenza vaccination patterns by race, education level, and rurality.

Researchers explored the impact of PCV10 on the distribution of invasive pneumococcal disease serotypes among patients in Lithuania.

Among participants in the CATCH trial, researchers explored the relationship between HPV vaccination and incidence of infection.

Searching for the clinical and economic impacts, researchers explored the implications of pharmacist-led anti-infective consultations.

FDA approves Biktarvy for HIV treatment in patients not virologically suppressed, enhancing options for those restarting antiretroviral therapy.

The decision makes the therapy the first and only twice-yearly option available in the United States for PrEP.

The therapy is the first and only oral direct acting antiviral approved by the FDA for HCV infection.